Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 32Myelodysplastic Syndromes 16Leukemia, Myelomonocytic, Chronic 7Recurrence 6Neoplasms 3Leukemia, Myelogenous, Chronic, BCR-ABL Positive 3Leukemia 3Leukemia, Myeloid 2Carcinoma, Non-Small-Cell Lung 2Thrombocythemia, Essential 1Primary Myelofibrosis 1Preleukemia 1Polycythemia Vera 1Pathologic Complete Response 1Myeloproliferative Disorders 1Melanoma 1Malignant Solid Tumor 1Hematologic Diseases 1Carcinoma, Renal Cell 1Bone Marrow Diseases 1Blast Crisis 1Advanced Breast Cancer 1

Interventions

venetoclax 1spartalizumab 1sabatolimab 1ruxolitinib 1lintuzumab 1filanesib 1Lenalidomide 1Decitabine 1CPI-0610 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Preleukemia × Decitabine × Clear all
NCT03066648 2025-05-18

Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With AML or High Risk MDS

Novartis

Phase 1 Completed
241 enrolled
MyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Leukemia, Leukemia, Myeloid, Myelodysplastic Syndromes, Preleukemia, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡